1. Home
  2. PLAB vs COAG Comparison

PLAB vs COAG Comparison

Compare PLAB & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Photronics Inc.

PLAB

Photronics Inc.

SELL

Current Price

$30.60

Market Cap

1.8B

Sector

Technology

ML Signal

SELL

COAG

Hemab Therapeutics Holdings Inc. Common Stock

N/A

Current Price

$28.44

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PLAB
COAG
Founded
1969
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.9B
IPO Year
1995
2026

Fundamental Metrics

Financial Performance
Metric
PLAB
COAG
Price
$30.60
$28.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$41.33
★ $61.20
AVG Volume (30 Days)
★ 739.7K
390.5K
Earning Date
08-26-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 9.09
N/A
EPS
★ 1.76
N/A
Revenue
★ $535,276,000.00
N/A
Revenue This Year
$2.20
N/A
Revenue Next Year
$2.81
N/A
P/E Ratio
$17.47
★ N/A
Revenue Growth
★ 18.77
N/A
52 Week Low
$20.05
$27.47
52 Week High
$56.00
$55.42

Technical Indicators

Market Signals
Indicator
PLAB
COAG
Relative Strength Index (RSI) 54.72 19.39
Support Level $27.43 N/A
Resistance Level $31.64 $38.87
Average True Range (ATR) 0.83 2.70
MACD 0.24 -0.73
Stochastic Oscillator 75.12 3.50

Price Performance

Historical Comparison
PLAB
COAG

About PLAB Photronics Inc.

Photronics Inc is a U.S.-based company principally engaged in the manufacturing of photomasks, which are high-precision photographic quartz or glass plates containing microscopic images of electronic circuits. Photomasks are a key element in the manufacture of integrated circuits (ICs) and flat-panel displays (FPDs) and are used as masters to transfer circuit patterns onto semiconductor wafers and FPD substrates during fabrication, as well as to a lesser extent, other types of electrical and optical components. The Company has manufacturing facilities in Taiwan, China, South Korea, the United States, and Europe, and generates revenue globally, with Taiwan contributing the majority of total revenue.

About COAG Hemab Therapeutics Holdings Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Share on Social Networks: